Differential predictive value of baseline tumor size according to PD-L1 expression in advanced NSCLC treated with immune checkpoint inhibitors
BTS was a significant predictor of ICI monotherapy efficacy in patients with TPS 1-49%. Patients with large tumors and intermediate PD-L1 expression derived limited benefit from monotherapy, suggesting that chemoimmunotherapy may be more effective in this subgroup.
Authors
- Akinori Watanabe (ORCID: https://orcid.org/0009-0001-2434-8023)
- Seiichiro Kusuhara
- Mikiko Kakegawa
- Ayumi Nishimura
- Yuki Akazawa (ORCID: https://orcid.org/0000-0002-2427-3690)
- Maito Nakano
- Jiichiro Sasaki
- Masayuki Shirasawa
- Hiroki Ito
- Hiroto Kurata
- Tomohiro Furo
- Toshitaka Maeno
- Takashi Sato
- Katsuhiko Naoki
- Jyunpei Endo
- Atsuko Watanabe
- Yoshiro Nakahara
Institutions
- Kitasato University (JP)
Publication Details
- Journal
- Cancer Treatment and Research Communications
- Published
- 2025-12-30
- DOI
- https://doi.org/10.1016/j.ctarc.2025.101087
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00